Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type

ObjectivePreclinical studies have emphasized the potential connection between BRCA specific domains defects and the activity of Poly ADP-ribose polymerase inhibitors (PARPi). Nevertheless, real-world evidence regarding the impact of BRCA domain defects and mutations on PARPi efficacy are limited. Th...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Roberto Buonaiuto, Giuseppe Neola, Aldo Caltavituro, Alessandra Longobardi, Federica Pia Mangiacotti, Amedeo Cefaliello, Maria Rosaria Lamia, Francesco Pepe, Jole Ventriglia, Umberto Malapelle, Giancarlo Troncone, Mario Giuliano, Grazia Arpino, Sandro Pignata, Carmine De Angelis
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2024-09-01
Серія:	Frontiers in Oncology
Предмети:	HGSOC PARP inhibitors BRCA mutation domain resistance ovarian cancer
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1412807/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type

Схожі ресурси